Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.

PMID:
18759107
2.

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.

Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME, Schwope I, Bolt-de Vries J, Harbeck N, Koenig T, Hartmann O, Kluth A, Dietrich D, Magdolen V, Portengen H, Look MP, Klijn JG, Lesche R, Schmitt M, Maier S, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2008 Oct;111(3):429-37. Epub 2007 Oct 28.

PMID:
17965955
3.

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.

Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3319-28.

4.

How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.

Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA.

Clin Cancer Res. 2005 Oct 15;11(20):7311-21.

5.

Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.

Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, Meijer-Van Gelder ME, Piepenbrock C, Olek A, Höfler H, Kiechle M, Klijn JG, Schmitt M, Maier S, Foekens JA.

Cancer Res. 2005 May 15;65(10):4101-17.

6.

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM.

J Clin Oncol. 2005 Feb 1;23(4):732-40.

PMID:
15681518
7.

The prognostic value of BCAR1 in patients with primary breast cancer.

Dorssers LC, Grebenchtchikov N, Brinkman A, Look MP, van Broekhoven SP, de Jong D, Peters HA, Portengen H, Meijer-van Gelder ME, Klijn JG, van Tienoven DT, Geurts-Moespot A, Span PN, Foekens JA, Sweep FC.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6194-202.

8.

Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue.

Grebenchtchikov N, Brinkman A, van Broekhoven SP, de Jong D, Geurts-Moespot A, Span PN, Peters HA, Portengen H, Foekens JA, Sweep CG, Dorssers LC.

Clin Chem. 2004 Aug;50(8):1356-63.

PMID:
15277346
9.

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA.

Clin Cancer Res. 2003 Apr;9(4):1253-8.

10.

Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features.

Berns EM, van Staveren IL, Verhoog L, van de Ouweland AM, Meijer-van Gelder M, Meijers-Heijboer H, Portengen H, Foekens JA, Dorssers LC, Klijn JG.

Br J Cancer. 2001 Aug 17;85(4):538-45.

11.

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG.

Cancer Res. 2000 Apr 15;60(8):2155-62.

12.

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.

Cancer Res. 2000 Feb 1;60(3):636-43.

13.

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.

Berns EM, Klijn JG, van Putten WL, de Witte HH, Look MP, Meijer-van Gelder ME, Willman K, Portengen H, Benraad TJ, Foekens JA.

J Clin Oncol. 1998 Jan;16(1):121-7.

PMID:
9440732
14.

Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment.

Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG.

Gene. 1995 Jun 14;159(1):11-8.

PMID:
7607564
15.

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG.

J Natl Cancer Inst. 1995 May 17;87(10):751-6.

PMID:
7563153
16.

Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen.

Foekens JA, Klijn JG, Natoli C, van Putten WL, Di Stefano P, Look MP, Portengen H, Iacobelli S.

Int J Cancer. 1995 Apr 21;64(2):130-4.

PMID:
7615355
17.

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

Foekens JA, Portengen H, Look MP, van Putten WL, Thirion B, Bontenbal M, Klijn JG.

Br J Cancer. 1994 Dec;70(6):1217-23.

18.

The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study.

Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL, Foekens JA.

Breast Cancer Res Treat. 1994 Jan;29(1):73-83.

PMID:
8018964
19.

Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs.

Rutteman GR, Foekens JA, Portengen H, Vos JH, Blankenstein MA, Teske E, Cornelisse CJ, Misdorp W.

Breast Cancer Res Treat. 1994;30(2):139-46.

PMID:
7949212
20.

Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.

Foekens JA, van Putten WL, Portengen H, de Koning HY, Thirion B, Alexieva-Figusch J, Klijn JG.

J Clin Oncol. 1993 May;11(5):899-908.

PMID:
8487052
21.

Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells.

van Agthoven T, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC.

Cancer Res. 1992 Sep 15;52(18):5082-8.

22.

Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification.

Berns EM, Foekens JA, van Putten WL, van Staveren IL, Portengen H, de Koning WC, Klijn JG.

J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):13-9.

PMID:
1356012
23.

c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.

Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA.

Cancer Res. 1992 Mar 1;52(5):1107-13.

24.

Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors.

Berns EM, Klijn JG, van Staveren IL, Portengen H, Foekens JA.

Cancer Res. 1992 Feb 15;52(4):1036-9.

25.

Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.

Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA.

Eur J Cancer. 1992;28(2-3):697-700.

PMID:
1350457
26.

Treatment of breast cancer with different antiprogestins: preclinical and clinical studies.

Bakker GH, Setyono-Han B, Portengen H, De Jong FH, Foekens JA, Klijn JG.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):789-94.

PMID:
2285592
27.

Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.

Foekens JA, van Putten WL, Portengen H, Rodenburg CJ, Reubi JC, Berns PM, Henzen-Logmans SC, van der Burg ME, Alexieva-Figusch J, Klijn JG.

J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):815-21.

PMID:
2178364
28.

The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors.

Bakker GH, Setyono-Han B, Foekens JA, Portengen H, van Putten WL, de Jong FH, Lamberts SW, Reubi JC, Klijn JG.

Breast Cancer Res Treat. 1990 Nov;17(1):23-32.

PMID:
1965705
29.

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.

Klijn JG, Hoff AM, Planting AS, Verweij J, Kok T, Lamberts SW, Portengen H, Foekens JA.

Br J Cancer. 1990 Oct;62(4):627-30.

30.

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7002-9.

31.

Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.

Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JG.

Cancer Res. 1989 Nov 1;49(21):5823-8.

32.
33.

Insulin-like growth factor-1 receptors and insulin-like growth factor-1-like activity in human primary breast cancer.

Foekens JA, Portengen H, Janssen M, Klijn JG.

Cancer. 1989 Jun 1;63(11):2139-47.

PMID:
2541884
34.

Comparison of enzyme immunoassay and dextran-coated charcoal techniques for progesterone receptor determination in human breast cancer cytosols.

Foekens JA, Portengen H, van Driel J, van Putten WL, Haije WG, Klijn JG.

J Steroid Biochem. 1988 Jun;29(6):571-4.

PMID:
3290577
35.

Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.

Teulings FA, van Gilse HA, Henkelman MS, Portengen H, Alexieva-Figusch J.

Cancer Res. 1980 Jul;40(7):2557-61.

36.

A new aspect of the urinary excretion of tryptophan metabolites in patients with cancer of the bladder.

Teulings FA, Peters HA, Hop WC, Fokkens W, Haije WG, Portengen H, van der Werf-Messing B.

Int J Cancer. 1978 Feb 15;21(2):140-6. No abstract available.

PMID:
627424
37.

Quantitation of estrogen receptors in human breast cancer by agar gel electrophoresis.

Teulings FA, Blonk-van der Wijst J, Portengen H, Henkelman MS, Treurniet RE, van Gilse HA.

Clin Chim Acta. 1975 Oct 1;64(1):27-38.

PMID:
171101
38.

The action of 3-hydroxyanthranilic acid and other tryptophan metabolites on stimulated human lymphocytes.

Teulings FA, Lems PH, Portengen H, Henkelman MS, Blonk DI.

Acta Vitaminol Enzymol. 1975;29(1-6):113-6.

PMID:
1244079

Supplemental Content

Loading ...
Support Center